Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

On a fourth-quarter earnings call with the media this morning, Novartis’ chief medical officer and head of development Shreeram Aradhye, M.D., told Fierce Biotech that the Swiss pharma had stopp ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. Now, the rising class of bispecifics opened up an opportunity for the Swiss pharma to reenter the space ...

Novartis sues HHS over rejection of a proposed 340B rebate model, arguing it enhances transparency and compliance while ...

Keros snagged $200 million upfront for the inhibitor drug. Also in the cancer therapeutics space, Swiss pharma giant Novartis and American biotech Olema Oncology have forged an alliance. Olema will ...

Hoffmann La Roche Ltd., Genmab AS, Gilead Sciences Inc., Johnson and Johnson Inc., Moderna Inc., Novartis AG, Novo Nordisk AS ... compliance and ensuring the safety and efficacy of biotech products.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Novartis shows strong bullish momentum, while AbbVie remains range-bound ahead of its Q4 earnings reports. Investors should watch key resistance levels — ABBV above $177 and NVS above $106 ...